The role of ACE inhibitors and ARBs in preserving cognitive function via hypertension Management: A critical Update

Area of Science:

• Neurology
• Pharmacology
• Gerontology

Background:

• Hypertension is a major risk factor for dementia and Alzheimer's disease.
• Aging populations worldwide face increasing rates of age-related neurological disorders.
• Current hypertension treatments, including angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs), have demonstrated neuroprotective potential.

Purpose of the Study:

• To investigate the comparative effects of ARBs and ACEIs on cognitive function and neurological health.
• To evaluate the neuroprotective properties and potential risks associated with these antihypertensive drug classes.

Main Methods:

• Review of observational studies and Alzheimer's disease models.
• Analysis of drug mechanisms, including blood-brain barrier penetration.
• Comparison of outcomes such as cognitive decline, dementia incidence, and brain volume changes.

Main Results:

• Both ARBs and ACEIs may influence cognition, with some evidence suggesting they can reduce cognitive impairment and amyloid buildup in Alzheimer's models.
• Observational data indicate potential independent contributions of these drug classes to cognitive decline.
• ARBs were associated with less brain shrinkage, lower dementia incidence, and slower cognitive decline compared to ACEIs.

Conclusions:

• ARBs may offer superior neuroprotection compared to ACEIs, potentially due to selective angiotensin type 1 receptor blockade.
• Further research is needed to clarify the long-term comparative effects of ARBs and ACEIs on cognitive health in hypertensive patients.
• Understanding these drug class differences is crucial for managing hypertension and mitigating dementia risk in aging populations.